These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 27321184)
1. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. Doudican NA; Orlow SJ Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184 [TBL] [Abstract][Full Text] [Related]
2. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
3. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304 [TBL] [Abstract][Full Text] [Related]
5. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151 [TBL] [Abstract][Full Text] [Related]
6. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306 [TBL] [Abstract][Full Text] [Related]
7. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964 [TBL] [Abstract][Full Text] [Related]
8. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688 [TBL] [Abstract][Full Text] [Related]
9. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Yoshida A; Lee EK; Diehl JA Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853 [TBL] [Abstract][Full Text] [Related]
11. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425 [TBL] [Abstract][Full Text] [Related]
12. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors. Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773 [TBL] [Abstract][Full Text] [Related]
13. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533 [TBL] [Abstract][Full Text] [Related]
14. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Polier G; Neumann J; Thuaud F; Ribeiro N; Gelhaus C; Schmidt H; Giaisi M; Köhler R; Müller WW; Proksch P; Leippe M; Janssen O; Désaubry L; Krammer PH; Li-Weber M Chem Biol; 2012 Sep; 19(9):1093-104. PubMed ID: 22999878 [TBL] [Abstract][Full Text] [Related]
16. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway. Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784 [TBL] [Abstract][Full Text] [Related]
17. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma. Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601 [TBL] [Abstract][Full Text] [Related]
18. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448 [TBL] [Abstract][Full Text] [Related]
19. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
20. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects. Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]